WS
CRDF icon

Wedbush Securities’s Cardiff Oncology CRDF Stock Holding History

Wedbush Securities’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-20,370
Closed -$21K – 967
2020
Q1 		$21K Sell
20,370
-5,537
-21% -$7.83K ﹤0.01% 861
2019
Q4 		$32K Buy
25,907
+12,337
+91% +$17.6K ﹤0.01% 976
2019
Q3 		$20K Buy
13,570
+3,500
+35% +$6.81K ﹤0.01% 970
2019
Q2 		$25K Buy
+10,070
New +$32.3K ﹤0.01% 968
2019
Q1 		– Sell
-6,767
Closed -$21K – 931
2018
Q4 		$21K Buy
+6,767
New +$30.9K ﹤0.01% 815

Other funds holding CRDF

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Wedbush Securities's CRDF Position: Q2 2020 in Review

Wedbush Securities sold out of Cardiff Oncology (CRDF) in Q2 2020, closing a stake of 20,370 shares — an estimated $21K sold.

Wedbush Securities first reported a position in CRDF in Q4 2018 and held it in 5 quarters. The position peaked at $32K in Q4 2019. 29 funds tracked by Wall St. Rank hold CRDF as of Q2 2020.

  • Wedbush Securities reported no remaining Cardiff Oncology position as of Q2 2020 after selling out during the quarter.
  • Wedbush Securities sold 20,370 Cardiff Oncology shares in Q2 2020, an estimated $21K.
  • Wedbush Securities first reported a position in Cardiff Oncology in Q4 2018 and held it in 5 quarters.
  • Wedbush Securities's Cardiff Oncology position peaked at $32K in Q4 2019.
  • 29 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2020.

Based on Wedbush Securities's 13F filing for Q2 2020, filed 16 Jul 2020.